IS2715B - Ný notkun fyrir búdesóníð og formóteról - Google Patents

Ný notkun fyrir búdesóníð og formóteról

Info

Publication number
IS2715B
IS2715B IS5407A IS5407A IS2715B IS 2715 B IS2715 B IS 2715B IS 5407 A IS5407 A IS 5407A IS 5407 A IS5407 A IS 5407A IS 2715 B IS2715 B IS 2715B
Authority
IS
Iceland
Prior art keywords
formoterol
budesonide
new use
new
relates
Prior art date
Application number
IS5407A
Other languages
English (en)
Icelandic (is)
Other versions
IS5407A (is
Inventor
Jan Trofast
Carl-Axel Bauer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2715(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS5407A publication Critical patent/IS5407A/is
Publication of IS2715B publication Critical patent/IS2715B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS5407A 1997-09-19 2000-03-15 Ný notkun fyrir búdesóníð og formóteról IS2715B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use
PCT/SE1998/001599 WO1999015182A1 (en) 1997-09-19 1998-09-09 New use for budesonide and formoterol

Publications (2)

Publication Number Publication Date
IS5407A IS5407A (is) 2000-03-15
IS2715B true IS2715B (is) 2011-02-15

Family

ID=20408325

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5407A IS2715B (is) 1997-09-19 2000-03-15 Ný notkun fyrir búdesóníð og formóteról

Country Status (38)

Country Link
US (2) US7897646B2 (enEXAMPLES)
EP (2) EP1014993B1 (enEXAMPLES)
JP (1) JP2001517630A (enEXAMPLES)
KR (1) KR20010024140A (enEXAMPLES)
CN (1) CN1149998C (enEXAMPLES)
AR (1) AR013506A1 (enEXAMPLES)
AT (2) ATE222106T1 (enEXAMPLES)
AU (1) AU757235B2 (enEXAMPLES)
BR (1) BR9812325A (enEXAMPLES)
CA (1) CA2302700C (enEXAMPLES)
CY (1) CY1106156T1 (enEXAMPLES)
CZ (1) CZ295250B6 (enEXAMPLES)
DE (2) DE69834955T2 (enEXAMPLES)
DK (2) DK1210943T3 (enEXAMPLES)
EE (1) EE04297B1 (enEXAMPLES)
ES (2) ES2182357T3 (enEXAMPLES)
HK (1) HK1045812B (enEXAMPLES)
HU (1) HUP0003848A2 (enEXAMPLES)
ID (1) ID24838A (enEXAMPLES)
IL (1) IL134773A (enEXAMPLES)
IN (1) IN190791B (enEXAMPLES)
IS (1) IS2715B (enEXAMPLES)
MX (1) MXPA00002615A (enEXAMPLES)
MY (1) MY127812A (enEXAMPLES)
NO (1) NO327176B1 (enEXAMPLES)
NZ (1) NZ503173A (enEXAMPLES)
PL (1) PL190782B1 (enEXAMPLES)
PT (2) PT1014993E (enEXAMPLES)
RU (1) RU2199322C2 (enEXAMPLES)
SA (1) SA98190773B1 (enEXAMPLES)
SE (1) SE9703407D0 (enEXAMPLES)
SI (2) SI1210943T1 (enEXAMPLES)
SK (1) SK285330B6 (enEXAMPLES)
TR (1) TR200000726T2 (enEXAMPLES)
TW (1) TW546140B (enEXAMPLES)
UA (1) UA72446C2 (enEXAMPLES)
WO (1) WO1999015182A1 (enEXAMPLES)
ZA (1) ZA988516B (enEXAMPLES)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
PT1283036E (pt) * 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
JP5154732B2 (ja) * 2001-02-06 2013-02-27 イノバータ・バイオメッド・リミテッド 薬剤
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
CA2500065A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
PL1921919T3 (pl) * 2005-07-14 2012-09-28 Lithera Inc Ulepszona lipolityczna formulacja o podtrzymywanym uwalnianiu do traktowania lokalnej tkanki tłuszczowej
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
KR20190049943A (ko) 2009-05-29 2019-05-09 펄 테라퓨틱스 인코포레이티드 활성제의 호흡기 전달
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
WO2011088413A2 (en) * 2010-01-15 2011-07-21 Lithera, Inc. Lyophilized cake formulations
EP2646012A4 (en) 2010-11-24 2014-12-10 Neothetics Inc MONOTHERAPEUTIC FORMULATIONS OF SELECTIVE, LIPOPHILIC AND PROLONGED BETA AGONISTS AND METHODS OF COSMETIC TREATMENT OF SILHOUETTE ADPOSITY AND REINFORCEMENT
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
EP2968152B2 (en) 2013-03-15 2022-06-22 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
BR122020022602B1 (pt) 2015-12-04 2024-03-05 Mexichem Fluor S.A. De C.V. Composição farmacêutica
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2021076701A1 (en) 2019-10-17 2021-04-22 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE92762T1 (de) 1989-09-08 1993-08-15 Glaxo Group Ltd Medikamente.
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
EP1101493A3 (en) 1991-12-18 2004-01-14 AstraZeneca AB New combination of formoterol and budesonide
WO1993011773A1 (en) 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
BR9611820A (pt) * 1995-11-24 1999-07-13 Smithkline Beecham Spa Derivados de quinolina
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1999000134A1 (en) 1997-06-27 1999-01-07 Astra Aktiebolag (Publ) New combination of antiasthma medicaments
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
WO1999015182A1 (en) 1999-04-01
EE04297B1 (et) 2004-06-15
PL190782B1 (pl) 2006-01-31
EP1210943B1 (en) 2006-06-14
IL134773A (en) 2005-03-20
PL339295A1 (en) 2000-12-04
HUP0003848A2 (hu) 2001-08-28
DE69834955T2 (de) 2007-01-25
JP2001517630A (ja) 2001-10-09
SK3892000A3 (en) 2000-12-11
DE69807239T2 (de) 2003-04-10
SI1014993T1 (en) 2003-02-28
SE9703407D0 (sv) 1997-09-19
DE69807239D1 (de) 2002-09-19
NO20001401L (no) 2000-03-17
NO20001401D0 (no) 2000-03-17
BR9812325A (pt) 2000-09-05
CA2302700C (en) 2010-11-23
US20020042404A1 (en) 2002-04-11
AU757235B2 (en) 2003-02-06
SA98190773B1 (ar) 2006-10-02
HK1045812B (en) 2006-12-22
EP1210943A1 (en) 2002-06-05
DK1014993T3 (da) 2002-11-11
EE200000145A (et) 2001-02-15
SK285330B6 (sk) 2006-11-03
IS5407A (is) 2000-03-15
NO327176B1 (no) 2009-05-04
MY127812A (en) 2006-12-29
PT1014993E (pt) 2002-12-31
US20060189587A9 (en) 2006-08-24
IN190791B (enEXAMPLES) 2003-08-23
HK1045812A1 (en) 2002-12-13
CA2302700A1 (en) 1999-04-01
NZ503173A (en) 2001-08-31
IL134773A0 (en) 2001-04-30
MXPA00002615A (es) 2002-04-24
DE69834955D1 (de) 2006-07-27
TW546140B (en) 2003-08-11
US20110097282A1 (en) 2011-04-28
UA72446C2 (uk) 2005-03-15
ID24838A (id) 2000-08-24
SI1210943T1 (sl) 2006-10-31
CZ2000950A3 (cs) 2000-06-14
EP1014993A1 (en) 2000-07-05
ES2182357T3 (es) 2003-03-01
ES2266322T3 (es) 2007-03-01
AU9192898A (en) 1999-04-12
TR200000726T2 (tr) 2000-09-21
ATE222106T1 (de) 2002-08-15
ZA988516B (en) 1999-03-19
PT1210943E (pt) 2006-09-29
US7897646B2 (en) 2011-03-01
CN1271287A (zh) 2000-10-25
AR013506A1 (es) 2000-12-27
ATE329599T1 (de) 2006-07-15
US8461211B2 (en) 2013-06-11
KR20010024140A (ko) 2001-03-26
RU2199322C2 (ru) 2003-02-27
DK1210943T3 (da) 2006-09-18
CY1106156T1 (el) 2011-06-08
CZ295250B6 (cs) 2005-06-15
EP1014993B1 (en) 2002-08-14
CN1149998C (zh) 2004-05-19

Similar Documents

Publication Publication Date Title
IS2715B (is) Ný notkun fyrir búdesóníð og formóteról
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE69838728D1 (de) Methoden und zusammensetzungen zum wirksameren abfangen von sauerstoff
FI970920L (fi) Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon
DE60010662D1 (de) Kombinationen von formoterol und fluticasonpropionat für asthma
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
DE69518919D1 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
FI971412A7 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä
FI972781L (fi) Menetelmät ja koostumukset allergisen nuhan ja muiden sairauksien hoitamiseksi käyttäen dekarboetokyloratadieeniä
NO20002846D0 (no) Inhaleringsanordning og fremgangsmÕte ved samme
FI964314A7 (fi) Substituoidut sulfonamidit selektiivisinä beta3-agonisteina diabeteksen ja liikalihavuuden hoitoon
NO971015D0 (no) Forbindelser og metoder for behandling av cancer
ATE201138T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
FI971151A7 (fi) Kolesterolin absorption inhibiittorin ja kolesterolin synteesin inhibi ittorin yhdistelmä
DE69528011D1 (de) Verfahren zur Pflege der Nägel
EE200000093A (et) Agrekanaasi ja maatriksmetalloproteinaaside uudsed inhibiitorid artriidi käitlemiseks
FI971750A0 (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
NO994631D0 (no) Fremgangsmaater og sammensetninger for behandling av eggstokkreft
NO952568D0 (no) Behandling av cellulosemateriale og blandinger for anvendelse for dette
NO972114D0 (no) Fremgangsmåte for behandling av H2S-holdige gass-strömmer
DE69418931D1 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
DK0981349T3 (da) 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme
DE59707847D1 (de) Einrichtung zum Herstellen und Verpacken von Zigaretten
NO964291D0 (no) Fremgangsmåte for behandling av allergisk rinitt